Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
41.85
-0.06 (-0.14%)
At close: Nov 4, 2026, 4:00 PM EST
41.70
-0.15 (-0.36%)
After-hours: Nov 4, 2026, 7:57 PM EST
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.40B in the quarter ending September 30, 2026, a decrease of -1.90%. This brings the company's total for the last twelve months to $17.23B, up 2.71% year-over-year. In the year 2025, Teva Pharmaceutical had annual revenue of $17.26B with 4.32% growth. That makes Teva Pharmaceutical the 880th largest company in the world by revenue and 296th in the United States.
Revenue (ttm)
$17.23B
Revenue Growth
+2.71%
P/S Ratio
2.83
Revenue / Employee
$507,511
Employees
33,950
Market Cap
48.83B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Teva Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.97B | -10.43% |
| Dec 31, 2018 | 18.85B | -3.00B | -13.72% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 29.86B |
| Haleon | 14.80B |
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Neurocrine Biosciences | 3.70B |
| Dr. Reddy's Laboratories | 3.44B |
| Amneal Pharmaceuticals | 3.20B |
TEVA News
- 15 hours ago - Teva price target raised to $57 from $55 at TD Cowen - TheFly
- 16 hours ago - Teva price target raised to $48 from $43 at BofA - TheFly
- 17 hours ago - Teva price target raised to $55 from $50 at Goldman Sachs - TheFly
- 18 hours ago - Teva price target raised to $54 from $52 at H.C. Wainwright - TheFly
- 1 day ago - Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo - Reuters
- 1 day ago - Teva says ‘very confident’ in trajectory of biosimilars business - TheFly
- 1 day ago - Teva reports Q3 EPS 86c, consensus 72c - TheFly
- 1 day ago - Teva sees FY26 EPS $1.92-$2.11, consensus $2.09 - TheFly